Aspire Biopharma | 10-Q: FY2025 Q3 Revenue: USD 1.941 K

Revenue: As of FY2025 Q3, the actual value is USD 1.941 K.

EPS: As of FY2025 Q3, the actual value is USD -0.04.

EBIT: As of FY2025 Q3, the actual value is USD -370.44 K.

Net Revenue: $1,941 for both the three and nine months ended September 30, 2025.

Gross Profit: $884 for both the three and nine months ended September 30, 2025.
General and Administrative Expenses: $512,993 for the three months ended September 30, 2025, compared to $191,578 for the same period in 2024. For the nine months ended September 30, 2025, the expenses were $15,982,233 compared to $410,805 for the same period in 2024.
Research and Development Expenses: $207,899 for the three months ended September 30, 2025, compared to $7,000 for the same period in 2024. For the nine months ended September 30, 2025, the expenses were $823,879 compared to $28,000 for the same period in 2024.
Sales and Marketing Expenses: $425,489 for the three months ended September 30, 2025, compared to $16,678 for the same period in 2024. For the nine months ended September 30, 2025, the expenses were $696,639 compared to $104,344 for the same period in 2024.
Loss from Operations: - $1,145,497 for the three months ended September 30, 2025, compared to - $215,256 for the same period in 2024. For the nine months ended September 30, 2025, the loss was - $17,501,867 compared to - $543,149 for the same period in 2024.
Net Loss: - $1,850,493 for the three months ended September 30, 2025, compared to - $216,269 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $19,773,114 compared to - $544,162 for the same period in 2024.

Net Cash Used in Operating Activities: - $3,995,648 for the nine months ended September 30, 2025, compared to - $744,755 for the same period in 2024.
Net Cash Provided by Financing Activities: $5,940,286 for the nine months ended September 30, 2025, compared to $750,122 for the same period in 2024.

Interest Expense: $1,480,058 for the three months ended September 30, 2025, and $2,297,882 for the nine months ended September 30, 2025.
Change in Fair Value of Derivative Liabilities and Convertible Notes: $775,062 for the three months ended September 30, 2025, and $390,744 for the nine months ended September 30, 2025.
Loss on Extinguishment of Debt: - $364,109 for the nine months ended September 30, 2025.

Aspire Biopharma Holdings, Inc. plans to generate revenue through developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company expects to commence commercialization activities by building a focused sales and marketing organization in the United States to sell its products, as well as creating a dedicated Medical Affairs team to support commercialization efforts.
The company plans to submit a section 505(b)(2) New Drug Application (NDA) for its high-dose aspirin product to the FDA in early 2026, following positive clinical trial results demonstrating faster aspirin bioavailability in the blood compared to aspirin tablets.

Aspire is exploring licensing possibilities for its melatonin sleep-aid product and other sublingually administered vitamins and supplements. The company is also developing formulations for other products, including semaglutide, anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and caffeine products.

The company intends to raise additional financing through issuances of additional equity to support further sales and marketing and research and development efforts. If additional financing is required from outside sources, the company may not be able to raise it on terms acceptable to the company or at all.